risedronate sodium actavis 35 mg apvalkotās tabletes
actavis group ptc ehf., iceland - nātrija rizedronāts - apvalkotās tabletes - 35 mg
risendros 35 mg apvalkotās tabletes
zentiva, k.s., czech republic - nātrija rizedronāts - apvalkotā tablete - 35 mg
norifaz 35 mg apvalkotās tabletes
adamed pharma s.a., poland - nātrija rizedronāts - apvalkotā tablete - 35 mg
risonate 35 mg apvalkotās tabletes
teva pharma b.v., netherlands - nātrija rizedronāts - apvalkotā tablete - 35 mg
melenor 35 mg apvalkotās tabletes
medochemie ltd., cyprus - nātrija rizedronāts - apvalkotā tablete - 35 mg
zoledronic acid teva generics
teva generics b.v - pain skābes monohidrāts - osteoporosis; osteitis deformans - bisphosphonates - Ārstēšana osteoporosisin pēc menopauzes, womenin pieaugušo menat paaugstināta riska lūzumu, tai skaitā ar pēdējo zemu traumas gūžas lūzumu. attieksmi pret osteoporozi, kas saistītas ar ilgtermiņa sistēmisko glikokortikoīdu therapyin pēc menopauzes, womenin pieaugušo menat paaugstinātu risku lūzums. Ārstēšana paget ir slimības, kaulu pieaugušajiem.
zoledronic acid teva pharma
teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - zāles kaulu slimību ārstēšanai - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. Ārstēšana paget ir slimības, kaulu pieaugušajiem.
anastrozole actavis 1 mg apvalkotās tabletes
actavis group ptc ehf., iceland - anastrozols - apvalkotās tabletes - 1 mg
anastrozole accord 1 mg apvalkotās tabletes
accord healthcare b.v., netherlands - anastrozols - apvalkotā tablete - 1 mg
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcija homeostāze - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.